Clinical Trials
87 trialsELEGANT
Stemline Therapeutics, Inc.
TAILORx
National Cancer Institute (NCI)
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Borstkanker Onderzoek Groep
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
EvoPAR-BR01
AstraZeneca
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI)
CAMBRIA-1
AstraZeneca
POWER II
University of Virginia
LoTam
Alliance for Clinical Trials in Oncology
GIM10-CONSENT
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
DEBRA
NRG Oncology
SERENA-6
AstraZeneca
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
EMBER-4
Eli Lilly and Company
RAMP 301
Verastem, Inc.
MNEMOSYNE
Centre Oscar Lambret
OPERA-01
Olema Pharmaceuticals, Inc.
FALCON
AstraZeneca
MECCA
Sun Yat-sen University
PATINA
Alliance Foundation Trials, LLC.
e3
SWOG Cancer Research Network
MONARCH plus
Eli Lilly and Company
MONARCH 3
Eli Lilly and Company
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
POETIC-A
Institute of Cancer Research, United Kingdom
OVELIA
Tolmar Inc.
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
PADA-1
UNICANCER
SERENA-4
AstraZeneca
AURA
Japanese Foundation for Cancer Research
AMBRE
UNICANCER
EMERALD
Stemline Therapeutics, Inc.
EUROPA
Azienda Ospedaliero-Universitaria Careggi
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CAMBRIA-2
AstraZeneca
SoFEA
Institute of Cancer Research, United Kingdom
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
SWE-Switch
Region Örebro County
IBIS-II DCIS
Queen Mary University of London
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
MONALEESA-7
Novartis
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Canadian Cancer Trials Group